ALC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Sales: $2.7 billion, up 6% year-over-year.
Surgical Franchise: Revenue of $1.5 billion, also up 6%.
- Implantable Sales: $438 million, up 1% (impacted by competitive pressures and supply issues).
- Consumables: $769 million, up 4%.
- Equipment: $253 million, up 23%, driven by Unity product momentum.
Vision Care: Sales of $1.2 billion, up 6%.
- Contact Lens Sales: $738 million, up 4%.
- Ocular Health: $487 million, up 10%.
Core Gross Margin: 63%, down 40 basis points year-over-year due to tariffs.
Core Operating Margin: 21.2%, flat year-over-year.
Core Diluted Earnings: $0.85 per share.
Free Cash Flow: $279 million, flat year-over-year.
Tariff Impact: $33 million in incremental charges.

2. Strategic Updates and Business Highlights

Strong market acceptance for new products, particularly in U.S. AT-IOLs, surgical equipment, consumables, and dry eye products.
Unity platform recognized with an Edison Award, enhancing surgeon control and efficiency.
New product launches such as PanOptix Pro and True Plus are expected to bolster market share.
Continued focus on AI to enhance operational efficiency across R&D, manufacturing, and commercial sectors.
Ocular health portfolio, particularly dry eye products like Tryptyr and SustainPro, showing strong growth and market share gains.

3. Forward Guidance and Outlook

Sales Growth: Expected constant currency growth of 5% to 7% for the year.
Operating Margin Expansion: Anticipated increase of 70 to 170 basis points, primarily in the second half of the year.
Core Diluted EPS Growth: Projected growth of 10% to 13%.
Tariff Rate: Revised assumption of approximately 10% for U.S. imports, down from 15%, with a $25 million reduction in tariff expense expected to be reinvested into the business.

4. Challenges and Points of Concern

Market Conditions: Ongoing softness in the cataract surgery market, with global procedure volumes growing only low single digits.
Competitive Pressures: Notable competition in the IOL market, particularly affecting international sales.
Supply Chain Issues: Specific supply challenges with the Hydrus product impacted implantable sales growth.
Geographic Weakness: Declines in China affecting overall performance, particularly in AT-IOL penetration.

5. Notable Q&A Insights

Management expressed confidence in achieving the 3% to 4% market growth guidance despite current challenges.
The U.S. cataract market is expected to stabilize, with increased surgical capacity anticipated as practices adapt to demand.
Tryptyr's strong refill rates and broad prescriber enthusiasm indicate positive market acceptance, with expectations for expanded coverage.
Unity product launches are expected to drive equipment growth, with a phased rollout strategy for new products.
Management remains focused on tuck-in acquisitions, with no significant changes to M&A strategy despite recent deal exits.

Overall, while Alcon demonstrated solid financial performance and strategic advancements in Q1 2026, it faces challenges from competitive pressures and market conditions that could impact future growth.

ALC — Alcon Inc.